Laurus Labs Q1 FY26 Results: Revenue ₹1,570 Cr

Why Laurus Labs results matter for investors

Laurus Labs’ quarterly numbers and the stock’s sharp moves have kept it in focus within the pharma - API and CRAMS space. The company’s press note on Q1 FY26 reported revenue of ₹1,570 crore and EBITDA of ₹389 crore with EBITDA margin at 24.8%. At the same time, market data points in the provided information show the share price reacting to earnings and broader positioning after a strong run over the past year. For investors, the key questions now centre on how durable the company’s growth is, what is driving margins, and whether the stock’s current price already reflects the improvements.

Laurus Labs share price snapshot (30 June 2026)

As of 30 June 2026, Laurus Labs share price was reported at ₹1,493.3. The stock opened at ₹1,500.3 and the previous close was also stated as ₹1,500.3. During the trading session, the share price moved between ₹1,485.00 and ₹1,507.50, with an average price for the day of ₹1,496.25. The 52-week low and high were listed as ₹704.00 and ₹1,531.20, respectively. The same dataset also highlighted that the stock had increased 38.1% over the past six months and 106.98% over the last year, indicating a strong base effect heading into results.

Q1 FY26 headline numbers from the company’s press note

In its press note titled “Laurus Labs Announces Q1 FY26 Results”, the company reported revenues at ₹1,570 crore. EBITDA was reported at ₹389 crore, with EBITDA margins at 24.8%. Another data point in the provided text states the firm’s revenue grew 31% to ₹1,570 crore in Q1 FY26 versus ₹1,195 crore in Q1 FY25. The same line attributes growth to increasing uptake in CDMO deliveries and healthy business fundamentals. These disclosures frame the quarter as one where scale improved while margins stayed above 20%.

Profit surge: what the reported YoY jump indicates

One of the most striking figures in the provided information is the net profit change for Q1 FY26. It states Laurus Labs’ net profit increased 1,154% in Q1 FY26 to ₹163 crore, compared with ₹13 crore a year ago. The same set of details also mentions the stock was last seen at ₹891.75 on NSE at one point, “soaring 6.45%”, showing how sharply the market can react around earnings updates. While the text does not provide a detailed bridge for profit growth, the combination of revenue expansion and sustained EBITDA margins suggests operating leverage may have played a role.

Business mix in focus: CDMO push and reduced ARV dependence

The provided information points to a strategic shift in Laurus Labs’ revenue mix over a five-year period. It states the company reduced ARV revenue contribution from 67% to 45%, while CDMO grew from 13% to 28% of total revenue. This mix shift matters because it can change the company’s growth profile and margin stability across cycles. The dataset also lists capability areas in CDMO such as small molecules, fermentation, ADCs, peptides, and biocatalysis. It additionally notes that CDMO contribution moved from 28% in FY24 to 49% in FY25 for small molecules, as per the supplied table.

Broader growth indicators shown in the dataset

Beyond the quarter, the dataset includes several growth and return measures investors commonly track. It lists “Revenue growth” at +3% for 1Y (TTM) and +4% for 3Y CAGR. For profit growth, it reports +21% for 1Y (TTM) and +4% for 3Y CAGR. It also lists “Quarterly Earnings Growth YOY” at 20.54, without additional context in the provided information. These figures, taken together, suggest the market is weighing both short-term momentum and medium-term consistency.

Full-year numbers and market capitalisation datapoints

The text states that for the full year FY2026-2027, revenue reached ₹6,861.28 crore and profit touched ₹889.85 crore. Separately, it notes that as of Mar ’26, Laurus Labs’ market capitalisation stood at ₹81,053.65 crores. Another snapshot in the provided information mentions market capitalisation at ₹54,461 crore alongside a close price of ₹1,008.80, indicating that market-cap figures vary across different time snapshots and price points included in the dataset. For investors, aligning each metric to its date is critical before drawing conclusions.

Returns and volatility: strong longer-term numbers, mixed short-term signals

The dataset includes multiple return series. “Laurus Labs Historical Returns” shows +8.06% (1 month), +51.13% (3 months), +106.98% (1 year), +309.19% (3 years), and +117.86% (5 years). Another table lists share price returns of 3.28% (1 day), -1.5% (1 week), -10.97% (1 month), 1.0% (3 months), and 68.01% (1 year). While these series are not dated consistently in the provided information, they collectively point to a stock that has delivered high longer-term returns but can swing sharply over shorter periods.

Street view: 12-month targets and split recommendations

The provided information includes an analysts’ 12-month price target set. It states an average target of ₹1,055.15 with a “-28.89% downside”, a high estimate of ₹1,370, and a low estimate of ₹510. It also states that 6 analysts recommend buying and 5 suggest selling, with an overall rating of Neutral. This split matters because it suggests the market is not aligned on how much of the earnings recovery and CDMO-led growth is already priced in.

Market impact and what investors will track next

From the information provided, the immediate market impact is visible in the stock’s intraday range around ₹1,485 to ₹1,507.5 on 30 June 2026, as well as the references to post-result price reactions elsewhere in the dataset. Operationally, the press note metrics highlight EBITDA margins at 24.8%, and the narrative attributes revenue growth to CDMO deliveries. Investors will likely keep watch on whether revenue growth remains near the 31% YoY pace cited for Q1 FY26, and whether margins stay above 20% as suggested in the dataset’s commentary on recent quarters. With the stock near its 52-week high zone (₹1,531.2) per the provided figures, expectations can remain sensitive to any deviation in quarterly execution.

Conclusion

Laurus Labs’ Q1 FY26 disclosures point to a quarter of revenue growth to ₹1,570 crore and EBITDA of ₹389 crore with 24.8% margins, alongside a sharp YoY rise in reported net profit to ₹163 crore. Market data in the provided information shows the stock trading around ₹1,493 on 30 June 2026 with a wide 52-week range of ₹704 to ₹1,531.2. The next set of updates on growth sustainability, CDMO traction, and margin direction will be key reference points for investors tracking the stock after a strong one-year run.